Inspira Technologies Oxy B.H.N. Ltd. (IINNW) 株式分析

企業概要

Inspira Technologies Oxy B.H.N. Ltd. (IINNW) is a specialty medical device firm focused on the research, development, manufacturing, and marketing of proprietary life support technologies designed to treat acute respiratory failure within the Israeli market. The company primarily offers the INSPIRA ART100, a specialized life support system utilized in clinical procedures to address critical respiratory needs. Regarding its operational scale, the firm employs 34 individuals and reports a trailing twelve-month revenue of $289,000. The absence of available market cap data and the modest revenue figure of less than $300,000 indicate that the company operates as a micro-cap entity with limited financial footprint relative to larger industry peers. This scale suggests the business is in a specialized niche rather than a mass-market sector, where revenue generation is currently constrained to specific regional applications and product lines. The small employee base further reflects a lean organizational structure typical of early-stage development firms or those with highly concentrated operational models.

財務健全性

The company's financial performance for the trailing twelve months reveals a significant disparity between top-line revenue and bottom-line profitability, with revenue at $289,000 contrasted against a net loss of $13,220,000. This massive gap between the modest revenue stream and the substantial net loss indicates a highly fragile cost structure where operating expenses vastly exceed income generation capabilities. The company generated an EBITDA of -$13,473,000, signaling that even before interest and taxes, the core operations are generating negative cash equivalents from its primary business activities. Free cash flow stands at -$5,668,375, which implies that the company is burning through its cash reserves to fund operations and potentially capital expenditures or research initiatives. Despite this burn rate, the balance sheet holds $3.16M in cash against $480,000 in debt, providing a temporary buffer for ongoing operational deficits. However, the debt-to-equity ratio of 20.66 suggests a highly leveraged position relative to equity, although the absolute debt load remains small in nominal terms. The current ratio of 1.56 indicates that the company possesses sufficient current assets to cover its current liabilities, suggesting acceptable short-term liquidity despite the profitability challenges. Return on Equity is calculated at -397.9% and Return on Assets at -127.0%, metrics that reveal management is currently unable to generate positive returns on the capital invested in the business. These negative return metrics underscore the difficulty of scaling profitability in a segment where initial investments in R&D and life support technology development are not yet yielding commercial returns.

バリュエーション評価

Trailing P/E and forward P/E ratios are unavailable (N/A) due to the company's negative earnings, meaning traditional price-to-earnings valuation methods cannot be applied to assess the stock's expected earnings trajectory or historical profitability efficiency. The price-to-book ratio is recorded at 1.54, which indicates that the market values the company's equity at approximately 54% above its net book value, a premium that investors may attribute to the potential of its proprietary life support technologies despite current losses. Since revenue-based metrics like price-to-sales and EV/EBITDA are unavailable or not applicable given the negative EBITDA, alternative valuation approaches must rely on asset backing or strategic potential rather than cash flow multiples. The stock has traded within a 52-week range with a high of $0.80 and a low of $0.05. Based on the provided data, the current trading price sits below the 52-week high of $0.80, reflecting the volatility and speculative nature of the shares. The beta of 2.33 indicates that the stock price is expected to exhibit significantly higher volatility than the broader market, moving approximately 133% more than the market index during periods of fluctuation. This high beta profile suggests that the share price is sensitive to market sentiment and may experience sharp swings independent of fundamental business developments.

Growth & Income

Revenue growth and earnings growth rates are unavailable (N/A) in the provided data, preventing a direct comparison of whether earnings are expanding faster or slower than the top line. The company does not pay dividends, as evidenced by the absence of a dividend yield and payout ratio, indicating that it retains all earnings to fund operations and growth initiatives rather than distributing income to shareholders. For non-dividend payers like Inspira Technologies Oxy B.H.N. Ltd., the absence of a payout ratio implies that the firm reinvests its limited cash flows and capital reserves back into the business, likely towards the research and development of its proprietary respiratory technologies. Consequently, the overall growth and income profile is characterized by a reliance on capital appreciation driven by future product adoption rather than current cash distributions or historical earnings growth. The company's strategy appears to prioritize long-term development of life support systems over immediate income generation for investors. This approach is typical for early-stage medical device companies that require significant reinvestment to achieve commercial viability in the treatment of acute respiratory failure.